Journal Mobile Options
Table of Contents
Vol. 85, No. 1, 2013
Issue release date: July 2013

Prophylactic Supraclavicular Radiotherapy after Surgery in High-Risk N1 Breast Cancer

Yu J.I. · Park W. · Shin K.H. · Lee N.K. · Choi D.H. · Huh S.J.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: To evaluate the role of prophylactic supraclavicular radiotherapy (RT) by comparing the clinical outcomes of locoregional recurrence (LRR) in high-risk N1 breast cancer. Methods: We performed a retrospective comparison study of 250 high-risk N1 breast cancer patients treated at two institutions. Patients were considered to be high-risk when they had more than two of the following risk factors: lymphovascular invasion, extracapsular extension, metastasis to more than two axillary lymph nodes (ALNs), or level II or higher ALN metastasis. We compared two groups treated with different adjuvant RT fields for the purpose of prophylactic supraclavicular RT (SCRT). Results: Among the 250 patients, 97 patients received SCRT while 153 did not. During follow-up, 32 patients (7 in the SCRT and 25 in the no-SCRT group) had recurrence, and LRR developed in 19 patients, 18 of whom had not received SCRT. In multivariate analysis, SCRT [hazard ratio (HR) 0.072; p = 0.011] and chemotherapy regimen (cyclophosphamide, Adriamycin, and taxane; TAC) were the significant prognostic factors in LRR-free survival (HR 0.385; p = 0.046), and chemotherapy regimen also showed significance for distant metastasis-free survival (HR 0.399; p = 0.037). Conclusions: Use of prophylactic SCRT may reduce the risk of LRR in patients with high-risk N1 breast cancer.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b trial. N Engl J Med 1997;337:949-955.
  2. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, Kamby C, Kjaer M, Gadeberg CC, Rasmussen BB, Blichert-Toft M, Mouridsen HT: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish breast cancer cooperative group dbcg 82c randomised trial. Lancet 1999;353:1641-1648.
  3. Overgaard M, Nielsen HM, Overgaard J: Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007;82:247-253.
  4. Reddy JP, Levy L, Oh JL, Strom EA, Perkins GH, Buchholz TA, Woodward WA: Long-term outcomes in patients with isolated supraclavicular nodal recurrence after mastectomy and doxorubicin-based chemotherapy for breast cancer. Int J Radiat Oncol Biol Phys 2011;80:1453-1457.
  5. McKinna F, Gothard L, Ashley S, Ebbs SR, Yarnold JR: Lymphatic relapse in women with early breast cancer: a difficult management problem. Eur J Cancer 1999;35:1065-1069.
  6. Galper S, Recht A, Silver B, Manola J, Gelman R, Schnitt SJ, Connolly JL, Harris JR: Factors associated with regional nodal failure in patients with early stage breast cancer with 0-3 positive axillary nodes following tangential irradiation alone. Int J Radiat Oncol Biol Phys 1999;45:1157-1166.
  7. Strom EA, Woodward WA, Katz A, Buchholz TA, Perkins GH, Jhingran A, Theriault R, Singletary E, Sahin A, McNeese MD: Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:1508-1513.
  8. Huang EY, Chen HC, Sun LM, Fang FM, Hsu HC, Hsiung CY, Huang YJ, Wang CY, Wang CJ: Multivariate analyses of locoregional recurrences and skin complications after postmastectomy radiotherapy using electrons or photons. Int J Radiat Oncol Biol Phys 2006;65:1389-1396.
  9. Norman SA, Localio AR, Kallan MJ, Weber AL, Torpey HA, Potashnik SL, Miller LT, Fox KR, DeMichele A, Solin LJ: Risk factors for lymphedema after breast cancer treatment. Cancer Epidemiol Biomarkers Prev 2010;19:2734-2746.
  10. Yu TK, Whitman GJ, Thames HD, Buzdar AU, Strom EA, Perkins GH, Schechter NR, McNeese MD, Kau SW, Thomas ES, Hortobagyi GN, Buchholz TA: Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst 2004;96:1676-1681.
  11. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology, V1. Fort Washington, NCCN, 2012.
  12. Yu JI, Park W, Huh SJ, Choi DH, Lim YH, Ahn JS, Yang JH, Nam SJ: Determining which patients require irradiation of the supraclavicular nodal area after surgery for N1 breast cancer. Int J Radiat Oncol Biol Phys 2010;78:1135-1141.
  13. National Institute for Health and Clinical Excellence: Early and locally advanced breast cancer. Cardiff, National Collaborating Center for Cancer, 2009.

    External Resources

  14. Korean Breast Cancer Society: Practice guideline for breast cancer. J Breast Cancer 2011.
  15. Yates L, Kirby A, Crichton S, Gillett C, Cane P, Fentiman I, Sawyer E: Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes. Int J Radiat Oncol Biol Phys 2012;82:2093-2103.
  16. Recht A, Pierce SM, Abner A, Vicini F, Osteen RT, Love SM, Silver B, Harris JR: Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol 1991;9:988-996.

    External Resources

  17. Siponen ET, Vaalavirta LA, Joensuu H, Leidenius MH: Axillary and supraclavicular recurrences are rare after axillary lymph node dissection in breast cancer. World J Surg 2012;36:295-302.
  18. Macdonal SM, Abi-Raad RF, Alm El-Din MA, Niemierko A, Kobayashi W, McGrath JJ, Goldberg SI, Powell S, Smith B, Taghian AG: Chest wall radiotherapy: middle ground for treatment of patients with one to three positive lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys 2009;75:1297-1303.
  19. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378:1707-1716.
  20. Liljegren G, Holmberg L, Bergh J, Lindgren A, Tabar L, Nordgren H, Adami HO: 10-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol 1999;17:2326-2333.

    External Resources

  21. McArdle CS, McMillan DC, Greenlaw N, Morrison DS: Adjuvant radiotherapy and chemotherapy in breast cancer: 30 year follow-up of survival. BMC Cancer 2010;10:398.
  22. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-2106.
  23. Vinh-Hung V, Verschraegen C: Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst 2004;96:115-121.
  24. Whelan T: An intergroup trial of regional nodal irradiation in early breast cancer (abstract). J Clin Oncol 2011;29:LBA1003.
  25. Coen JJ, Taghian AG, Kachnic LA, Assaad SI, Powell SN: Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys 2003;55:1209-1215.
  26. Hayes SB, Freedman GM, Li T, Anderson PR, Ross E: Does axillary boost increase lymphedema compared with supraclavicular radiation alone after breast conservation? Int J Radiat Oncol Biol Phys 2008;72:1449-1455.
  27. Powell S, Taghian A, Kachnic L, Coen J, Assaad S: Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys 2003;55:1209-1215.
  28. Deutsch M, Land S, Begovic M, Sharif S: The incidence of arm edema in women with breast cancer randomized on the national surgical adjuvant breast and bowel project study B-04 to radical mastectomy versus total mastectomy and radiotherapy versus total mastectomy alone. Int J Radiat Oncol Biol Phys 2008;70:1020-1024.
  29. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007;356:217-226.
  30. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50